SMS Pharmaceuticals Limited concluded its 38th Annual General Meeting on September 29, 2026, with shareholders approving the audited financial statements for FY26 and the declaration of a dividend on equity shares. The meeting, conducted via video conference, also ratified the re-appointment of Chairman and Managing Director Ramesh Babu Potluri.

The AGM was held in compliance with the Companies Act, 2013 and SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. Chairman Ramesh Babu Potluri chaired the session, declaring a quorum was present. Due to regulatory guidelines, physical attendance was not required, and proxy appointments were not applicable.

Key resolutions passed

Shareholders voted on several ordinary and special business items. The adoption of standalone and consolidated financial statements for the year ended March 31, 2026, received approval alongside the dividend declaration. Additionally, Dr. Sunkara Venkata Satya Shiva Prasad was re-appointed as a director retiring by rotation.

Special business included the approval of material related party transactions with VKT Pharma Private Limited and remuneration for cost auditors for FY27. Two special resolutions were passed: one for the re-appointment of Ramesh Babu Potluri as CMD with fixed remuneration, and another authorizing a loan to subsidiary SMS Peptides Private Limited.

Governance and attendance

The meeting saw participation from the full board, including Independent Directors Shravan Kudaravalli, Sarvepalli Srinivas, Dr. Suresh Kumar Gangavarapu, and Mrs. Shanti Sree Bolleni. Executive Director Vamsi Krishna Potluri and Non-Executive Directors Dr. Sunkara Venkata Satya Shiva Prasad and Trilok Potluri were also present. Statutory auditors from M/s Suryanarayana & Suresh Chartered Accountants attended virtually.

E-voting was facilitated by Central Depository Services (India) Limited, with remote voting open from September 25 to September 28, 2026. Mr. C. Sudhir Babu of M/s CSB Associates served as the scrutinizer for the e-voting process. The consolidated results of the remote and live e-voting are expected to be announced within two working days.

SMS Pharmaceuticals will host a group analyst and institutional investor meeting in Hyderabad on September 15, 2026. The company disclosed the schedule under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

The interaction is scheduled with Emkay Global Investors. Management confirmed that discussions will focus on industry and company-specific developments already in the public domain. No unpublished price-sensitive information will be shared during the session.

Meeting Details

The company noted that the schedule remains subject to change due to exigencies involving the analysts, investors, or the firm itself. Thirumalesh Tumma, Company Secretary, signed the disclosure filed with the BSE and NSE on September 10, 2026.